Visano Theranostics is transforming the landscape of medical imaging and therapy with our innovative nanobubble technology, designed to outperform traditional ultrasound contrast agents. Our nanobubbles last up to 20 times longer than microbubbles, providing extended imaging windows and enhanced diagnostic precision. Their nanoscale size allows for superior tissue penetration and the ability to target both vascular and extravascular biomarkers, unlocking applications beyond the reach of conventional agents. With a high yield production process and tunable properties, our platform supports a broad range of clinical uses, from foundational imaging to targeted diagnostics and ultrasound-mediated theranostics. This versatility positions Visano as a leader in advancing cost-effective, real-time ultrasound solutions that improve patient outcomes, reduce healthcare costs, and expand access to cutting-edge theranostics globally.
| Website | https://www.visanotheranostics.com |
| Employees | 1 (1 on RocketReach) |
| Founded | 2024 |
| Industry | Biotechnology Research |
Looking for a particular Visano Theranostics employee's phone or email?
Michael Haag is the Chief Executive Officer and Founder of Visano Theranostics.
1 people are employed at Visano Theranostics.